Jubilant Pharmova Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 500% at ₹5/Share	24-Jul-2026	24-Jul-2026
DividendsFinal Dividend of 500% at ₹5/Share	25-Jul-2025	25-Jul-2025

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
Bandhan Small Cap Fund - Regular Plan - Growth	44.17 Lac	48.73 Lac (10.33%)
Quant Small Cap Fund - Growth	29.47 Lac	29.47 Lac no change
Kotak Multi Cap Fund - Regular Plan - Growth	18.74 Lac	18.29 Lac (2.41%)
Bandhan Focused Fund - Regular Plan - Growth	12.08 Lac	12.62 Lac (4.47%)
Abakkus Flexi Cap Fund - Regular Plan - Growth	5.52 Lac	6.14 Lac (11.24%)

CA Sumit Mangla

21 Oct • 5:43 PM · SEBI-Registered Analyst

Jubilant Pharmova assigned IND AA+/Stable to ₹1,400 Cr NCDs.

JUBLPHARMA

Jubilant Pharmova Limited (JUBLPHARMA) has received a credit rating assignment from India Ratings and Research Pvt Ltd. The rating is for proposed non-convertible debentures amounting to ₹1,400 crore. The instrument is Proposed Non-Convertible Debentures of ₹1,400 crore. The assigned rating is IND AA+/Stable. The rating action is Assigned. The key trigger is the assignment of an IND AA+/Stable rating for the proposed ₹1,400 crore NCD issuance, which supports the company’s funding plans without equity dilution. This reflects a favourable view of its credit profile in the specialty pharmaceuticals and CDMO space. Peers such as Syngene International, Piramal Pharma, and Divi’s Laboratories may face comparison on balance-sheet strength and debt-raising capacity. Near-term prices could see a mild positive reaction on the rating assignment and funding visibility. Risks include the final terms of the NCD issuance or any subsequent pressure on leverage metrics. Competitors listed: Syngene International, Piramal Pharma, Divi’s Laboratories.

Manjushri Sharma SEBI RA

13 Oct • 6:40 PM · SEBI-Registered Analyst

Jubilant Pharmova Shares in Focus Following Major Block Deal

JUBLPHARMA

Jubiliant Pharmova attracted market attention after Quant Mutual Fund reportedly sold approximately 20.81 lakh shares worth ₹190.47 crore through bulk deals. Abakkus Four2Eight Opportunities was reported among the buyers making the transaction an important development for investors tracking institutional activity in pharmaceutical stocks. Bulk and block deals can provide insights into changes in institutional ownership and market participation. However such transactions do not automatically indicate whether a stock is bullish or bearish. The impact depends on the transaction price prevailing valuations business fundamentals and subsequent price action. Investors should monitor trading volumes support and resistance levels quarterly performance and official exchange disclosures before drawing conclusions. A large transaction may create short-term volatility but the company's long-term prospects ultimately depend on earnings quality business growth and financial performance. Important Disclaimer: This article is for informational purposes only and is not a recommendation to buy or sell Jubilant Pharmova shares. Investors should verify exchange disclosures and conduct independent research before making investment decisions. Investments in securities are subject to market risks.

Sunil Kotak

13 Oct • 9:08 AM · SEBI-Registered Analyst

Jubilant Pharmova approves ₹800 crore NCD issue

JUBLPHARMA

Jubilant Pharmova approves ₹800 crore NCD issue SEBI RA – Shubh Consultancy – Sunil Kotak – INH000015826 Jubilant Pharmova Ltd on Monday said its Board of Directors has approved the issuance of non-convertible debentures (NCDs) aggregating up to Rs 800 crore on a private placement basis. According to a regulatory filing, the board approved the issue of up to 80,000 fully paid-up, rupee-denominated, secured or unsecured, rated, listed, redeemable, and transferable NCDs of face value Rs 1,00,000 each in one or more tranches, subject to applicable laws and regulatory approvals. The debentures are proposed to be listed on the BSE and carry a tenure of up to five years from the deemed date of allotment. The coupon or interest rate will be determined during the bidding process. Additionally, the board approved seeking shareholders' authorisation via a special resolution through postal ballot to issue non-convertible debt securities on a private placement basis. This authorisation covers an aggregate amount not exceeding Rs 2,500 crore outstanding at any point in time during a period of one year from the date of passing the resolution. All this is for information This is not a buy/sell recommendation. Thank you, Technofunda24

Sarathi Research

11 Oct • 10:29 PM · SEBI-Registered Analyst

Jubilant Pharmova Steadies After Fall, NCD Call Ahead

JUBLPHARMA

Jubilant Pharmova shares closed nearly flat at Rs 931.90 on Friday, stabilising after Thursday's sharp 4.35% fall, as the pharma and contract manufacturing company heads into a board meeting on October 12 to weigh raising funds via non-convertible debentures on private placement. Thursday's drop came amid broader market weakness, but it also sets the stage for this week's board decision on an NCD issuance, a debt-based fundraising route rather than fresh equity. Jubilant Pharmova runs a diversified business spanning contract manufacturing of sterile injectables, radiopharmaceuticals, and its own branded formulations and allergy therapy franchise, a mix needing steady capital for plant upgrades and capacity expansion across geographies. Contract development and manufacturing businesses live and die by passing regulatory inspections and keeping capacity running at scale, making timely capital access important for staying competitive against global peers. Choosing debt over equity suggests management wants to avoid diluting shareholders while funding capex, though an NCD also adds interest obligations the company must service regardless of near-term earnings swings, a trade-off investors in capital-intensive pharma watch closely. The stock has ranged between Rs 786.05 and Rs 1,184.80 over the past 52 weeks, with a market cap of around Rs 14,845 crore, trading well below its yearly high. With the board decision days away, how the funds are deployed, and at what cost, will likely shape sentiment more than Thursday's one-day dip. Disclosure: Palash Kag, Proprietor, Sarathi Research (SEBI Reg. No. INH000012740). No position held in Jubilant Pharmova. This article is for educational and informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Please consult a registered advisor before making investment decisions.

Pyrifera Investment Advisors

9 Oct • 11:33 AM · SEBI-Registered Analyst

Jubilant Pharmova expands Canadian radiopharma plant

Jubilant Pharmova is investing CAD 94.5 million to double the production capacity of its RUBY-FILL cardiac imaging agent in Canada. The project is backed by CAD 23.8 million in non-dilutive government funding, securing a high-margin growth engine. The expansion at the Kirkland, Québec facility targets a customer base that has doubled over the last three years. This matters because it aligns supply with proven, non-speculative demand in the high-barrier radiopharmaceuticals market. I am watching the Q3 FY27 earnings call for the exact timeline of the facility's modernization completion and the sequential margin impact of the CAD 23.8 million grant on the project's return on capital. The market often prices Jubilant Pharmova purely on its domestic API and CDMO volatility. What the consensus misses is the structural margin defense and valuation premium this specific expansion offers. Step one: RUBY-FILL operates in a high-barrier nuclear medicine niche with inelastic demand. Step two: doubling capacity captures the entire upside of a customer base that has already doubled, without proportional capex bloat. Step three: the CAD 23.8 million government grant acts as a direct subsidy, mechanically boosting the internal rate of return (IRR) and shielding the parent's balance sheet from foreign currency capex drag. The market views this as routine overseas capex, ignoring it is a highly subsidized, de-risked moat expansion. Accumulate for long-term high-margin radiopharma growth. Disclosure: I do not hold positions in this stock. This is for educational purposes only and does not constitute investment advice.

JUBLPHARMA

DHARMESH BHATT R A

8 Oct • 11:22 PM · SEBI-Registered Analyst

Jubilant Pharmova : to invest CAD 94.5

DHARMESH BHATT SEBI Registered Research Analyst — INH000009685

JUBLPHARMA

Jubilant Pharmova Limited has officially announced a significant CAD 94.5 million expansion and modernization project for its Kirkland, Québec facility in Canada. Managed through Jubilant Draximage Inc.—a subsidiary of the company’s wholly owned arm, Jubilant Pharma Limited—the expansion will double the production capacity of the company's flagship radiopharmaceutical product, RUBY-FILL®. The expansion project is backed by financial support from the Government of Canada, which is providing CAD 23.8 million via its Strategic Response Fund's innovation funding stream. * Meeting High Global Demand in Precision Medicine : The investment decision comes as market demand for diagnostic nuclear medicine solutions continues to rise. RUBY-FILL® enables the on-site generation of Rubidium-82, an agent vital for cardiac Positron Emission Tomography (PET) imaging used by cardiologists to evaluate coronary artery disease. *Corporate Context & Market Footprint: Jubilant Radiopharma operates as an integrated developer, manufacturer, and distributor. In the United States, its distribution network represents the second-largest radiopharmacy network, spanning 45 specialized pharmacies supplying nuclear medicine to health systems, imaging centers, and hospitals. Parent company Jubilant Pharmova Limited operates across multiple healthcare domains, including Radiopharma, Allergy Immunotherapy, Sterile Injectable CDMO, Drug Discovery CDMO, Generics, and Proprietary Novel Drugs, employing approximately 5,500 people globally Note : kindly click the link : Disclaimer/Disclosure in Bio

Jubilant Pharmova Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Jubilant Pharmova Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Jubilant Pharmova Ltd.?

What is the market cap of Jubilant Pharmova Ltd.?

Should I buy Jubilant Pharmova Ltd. stock now?

What is the 52 week high and low of Jubilant Pharmova Ltd.?

Is the Jubilant Pharmova Ltd. stock good to buy?

Is Jubilant Pharmova Ltd. a good buy for the long term?

Is Jubilant Pharmova Ltd. overvalued or undervalued?

What is the PE and PB ratio of Jubilant Pharmova Ltd.?